Ken Griffin Kal Vista Pharmaceuticals, Inc. Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Kal Vista Pharmaceuticals, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 15,600 shares of KALV stock, worth $182,052. This represents 0.0% of its overall portfolio holdings.
Number of Shares
15,600
Previous 50,100
68.86%
Holding current value
$182,052
Previous $613,000
69.82%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding KALV
# of Institutions
131Shares Held
46.5MCall Options Held
113KPut Options Held
72K-
Vr Adviser, LLC New York, NY6.25MShares$72.9 Million6.36% of portfolio
-
Suvretta Capital Management, LLC New York, NY4.19MShares$48.9 Million2.13% of portfolio
-
Tang Capital Management LLC San Diego, CA4.13MShares$48.1 Million5.96% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.69MShares$43 Million2.3% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA2.58MShares$30.1 Million0.06% of portfolio
About KalVista Pharmaceuticals, Inc.
- Ticker KALV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,602,000
- Market Cap $287M
- Description
- KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral p...